Acid-Fast (Mycobacteria) Antibiotic Susceptibilities
| Acid-Fast (Mycobacteria) Antibiotic Susceptibilities | | | |
| Number | | 088161 |
| CPT | | 87190 (x4, variable depending on identification) |
| Related Information | | Acid-Fast (Mycobacteria) Broth-Based Culture and Smear Acid-Fast (Mycobacteria) Broth-Based Culture and Smear and Susceptibility Organism Identification, Mycobacteria |
| Synonyms | | AFB Susceptibility Testing ; Rapid Grower Susceptibility Testing ; Susceptibility Testing, AFB ; TB Susceptibility Testing |
| Test Includes | | Antimycobacterial agents tested against isolates at appropriate concentrations and drugs depending on identification of the isolate. Identification is required to perform or provide an accurate interpretation for susceptibility testing, it will be done at an additional charge automatically. |
| Special Instructions | | Culture must be in special etiologic agent packaging for shipment to LabCorp. |
| Specimen | | Isolated mycobacteria from primary clinical specimen on media slant or in broth |
| Container | | Media slant, tightly sealed, in etiologic agent packaging |
| Storage Instructions | | Maintain culture at room temperature. |
| Causes for Rejection | | Specimen received leaking or in broken transport tube or vial; specimen received in expired transport media; mixed culture; unlabeled culture or name discrepancy between specimen and request label |
| Use | | Determine the susceptibility of the isolated organism to a profile of antimycobacterial agents |
| Limitations | | Susceptibilities cannot be reported if the organism fails to grow on test media. |
| Methodology | | Bactec® or other broth-based method, conventional proportion method. Newer methods (eg, MIC) will be introduced when validated. |
| Additional Information | | Susceptibilities should be performed on the first organism isolated from a patient, and at 1- to 3-month intervals if that organism continues to be isolated while the patient is on therapy. Susceptibility tests should be performed in patients with recurrent tuberculosis as resistant strains are common in recurrent infection. Outbreaks have occurred in healthcare workers, prison inmates, and prison employees.1,2 Failure to take all drugs in a multidrug regimen can lead to a shift toward resistant organisms and treatment failure. Nontuberculous mycobacteria, particularly strains of the M. avium complex, are resistant to those drugs used for therapy of M. tuberculosis.3 |
| Footnotes | | - Beck-Sague C, Dooley Sw, Hutton MD, et al, “Hospital Outbreak of Multidrug-Resistant Mycobacterium tuberculosis Infections. Factors in Transmission to Staff and HIV-Infected Patients,” JAMA, 1992, 268(10):1280-6.
- Dooley SW, Villarino ME, Lawrence M, et al, “Nosocomial Transmission of Tuberculosis in a Hospital Unit for HIV-Infected Patients,” JAMA, 1992, 267(19):2632-4.
- Wolinsky E, “Mycobacterial Diseases Other Than Tuberculosis,” Clin Infect Dis, 1992, 15(1):1-10
|
| References | | Heifets L, “Qualitative and Quantitative Drug Susceptibility Tests in Mycobacteriology,” Am Rev Respir Dis, 1988, 137(5):1217-22. Mor N and Heifets L, “MICs and MBCs of Clarithromycin Against Mycobacterium avium Within Human Macrophages,” Antimicrob Agents Chemother, 1993, 37(1):111-4. Rastogi N and Goh KS, “Effect of pH on Radiometric MICs of Clarithromycin Against 18 Species of Mycobacteria,” Antimicrob Agents Chemother, 1992, 36(12):2841-2. Van Scoy RE and Wilkowske CJ, “Antituberculous Agents,” Mayo Clin Proc, 1992, 67(2):179-87. |
|